Fondazione IRCCS Istituto Nazionale dei Tumori-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2021

  1. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

    Vaccine, Vol. 39, Núm. 20, pp. 2800-2809